Technical Data
C9095-19X1
CYP19A1 (Cytochrome P450 19A1, CYPXIX, Estrogen Synthetase, P-450AROM, Aromatase, Cytochrome P-450AROM, ARO1, CYAR, CYP19)
Description:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.

Applications:
Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
ELISA: 1:128,000
Western Blot: 0.1-0.3ug/ml, observed in human placenta lysates on ~50-55kD bands
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabAffinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanGoat
Concentration:
~0.5mg/ml
Immunogen:
Synthetic peptide corresponding to sequence C-HDLSLHPDETKN, from human CYP19A1, at the internal region of the protein (NP_000094.2, NP_112503.1).
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in Tris saline, 0.02% sodium azide, pH 7.3, 0.5% BSA.
Specificity:
Recognizes human CYP19A1.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Van Poznak CH, Hayes DF. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only? J Natl Cancer Inst. 2006 Sep 20;98(18):1261-3.